{"url_path":"/sec/inti/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1042418/0001493152-26-023622-index.html","accession_number":"0001493152-26-023622","cik":"0001042418","ticker":"INTI","issuer_name":"Inhibitor Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1042418/0001493152-26-023622-index.html","primary_entity_key":"0001042418","primary_entity_name":"Inhibitor Therapeutics, Inc."},"word_count":213,"has_tables":true,"body_markdown":"**Item\n6. Exhibits.**\n\n \n\n**Number**\n \n**Description**\n\n \n \n \n\n31.1\n \n[Certification of Chief Executive Officer Pursuant to Sarbanes-Oxley Section 302](ex31-1.htm)\n\n \n \n \n\n31.2\n \n[Certification of Interim Chief Financial Officer Pursuant to Sarbanes-Oxley Section 302](ex31-2.htm)\n\n \n \n \n\n32.1\n \n[Certification Pursuant To 18 U.S.C. Section 1350 (*)](ex32-1.htm)\n\n \n \n \n\n32.2\n \n[Certification Pursuant To 18 U.S.C. Section 1350 (*)](ex32-2.htm)\n\n \n \n \n\n101.ins\n \nXBRL\nInstance Document\n\n \n \n \n\n101.sch\n \nXBRL\nTaxonomy Extension Schema Document\n\n \n \n \n\n101.cal\n \nXBRL\nTaxonomy Calculation Linkbase Document\n\n \n \n \n\n101.def\n \nXBRL\nTaxonomy Definition Linkbase Document\n\n \n \n \n\n101.lab\n \nXBRL\nTaxonomy Label Linkbase Document\n\n \n \n \n\n101.pre\n \nXBRL\nTaxonomy Presentation Linkbase Document\n\n \n \n \n\n104\n \nThe\ncover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in Inline XBRL.\n\n \n \n \n\n*\n \nA\nsigned original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company\nand furnished to the Securities and Exchange Commission or its staff upon request.\n\n \n\n14\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto\nduly authorized.\n\n \n\n \nINHIBITOR\nTHERAPEUTICS, INC.\n\n \n \n \n\nDate:\nMay 15, 2026\nBy:\n*/s/\nFrancis E. O’Donnell*\n\n \n \nFrancis\nE. O’Donnell\n\n \n \nChief\nExecutive Officer\n\n \n \n(Principal\nExecutive Officer)\n\n \n\nDate:\nMay 15, 2026\nBy:\n*/s/\nJames A. McNulty*\n\n \n \nJames\nA. McNulty\n\n \n \nInterim\nChief Financial Officer, Treasurer and Secretary\n\n \n \n(Principal\nFinancial Officer)\n\n \n\n15\n\n****\n\n****"}